Released May 11, 2023, after the close
10-Q filed May 11, 2023, 41 days after period end · 0000950170-23-021187
Q1 2023 · 10-Q
Revenue$223.00K$223.00K −9.7% vs Q1 2022−19.8% vs Q4 2022
Net Income-$13.30M-$13.30M N/M vs Q1 2022N/M vs Q4 2022
EPS Diluted-$0.25-$0.25 N/M vs Q1 2022no prior Q4 2022 on file
Operating Income-$14,227,000N/M
Operating Cash Flow-$12,853,000N/M
Margins · derived
Operating margin-6379.8%+5849.7 pt vs Q1 2022
Net margin-5964.1%+7315.2 pt vs Q1 2022
What the release said
The release
Same quarter
| Metric | Q1 2023 | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|---|
| Revenue | $223.00K | $247.00K | $7.30M | $169.00K |
| Net Income | -$13.30M | -$32.80M | -$19.40M | -$23.30M |
| EPS Diluted | -$0.25 | -$1.01 | -$0.66 | -$1.22 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR